Stockscreener 앱 받기
28.67
0.55%
-0.16
시간 외 거래:
28.74
0.07
+0.24%
전일 마감가:
$28.83
열려 있는:
$28.8
하루 거래량:
913.59K
Relative Volume:
0.60
시가총액:
$1.67B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
2.5238
EPS:
11.36
순현금흐름:
$-330.11M
1주 성능:
+7.46%
1개월 성능:
+2.32%
6개월 성능:
-28.32%
1년 성능:
-15.05%
1일 변동 폭
$28.42
$29.93
1주일 범위
$26.42
$29.93
52주 변동 폭
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.67 | 1.68B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Aug Summary: Does Agios Pharmaceuticals Inc have a competitive edge2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - marketscreener.com
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewswire Inc.
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail
Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory - Finviz
Pharma News: Will Agios Pharmaceuticals Inc face regulatory challengesWeekly Gains Report & Daily Momentum Trading Reports - baoquankhu1.vn
What is Agios Pharmaceuticals Inc.’s market positionQuarterly Growth Report & Fast Moving Trade Plans - bollywoodhelpline.com
Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst - MarketBeat
A Look At Agios Pharmaceuticals (AGIO) Valuation After AQVESME FDA Approval And Commercial Launch - Sahm
Agios begins U.S. launch of thalassemia drug following FDA approval By Investing.com - Investing.com Nigeria
Is Agios’ AQVESME Thalassemia Launch and Sickle Cell Pathway Altering The Investment Case For Agios Pharmaceuticals (AGIO)? - Sahm
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sectors Review: Is Agios Pharmaceuticals Inc stock influenced by commodity pricesEarnings Performance Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline - MarketBeat
Agios Pharmaceuticals outlines 2026 strategic priorities - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Exploring a 29.77% Potential Upside in Biotechnology - DirectorsTalk Interviews
Weekly Recap: How Agios Pharmaceuticals Inc. stock valuations compare to rivalsWatch List & Accurate Buy Signal Notifications - Bộ Nội Vụ
Sickle Cell Disease Treatment Market is Thriving Worldwide | - openPR.com
Ideas Watch: Is Agios Pharmaceuticals Inc stock good for income investorsJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Agios begins U.S. launch of thalassemia drug following FDA approval - Investing.com
Agios Pharmaceuticals Outlines 2026 Strategic Priorities and Milestones - TradingView — Track All Markets
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - The Manila Times
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease ... - caledonianrecord.com
New anemia pill and sickle cell trials set up big year in rare disease care - Stock Titan
Published on: 2026-01-11 10:51:52 - ulpravda.ru
Peregrine Capital Management LLC Makes New $6.54 Million Investment in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. stock performs in rate cut cycles2025 Big Picture & Technical Pattern Based Buy Signals - ulpravda.ru
Agios Pharmaceuticals plunges as Phase 3 sickle cell results deliver a mixed picture - MSN
(AGIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
AGIO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money - ACCESS Newswire
What Wall Street predicts for Agios Pharmaceuticals Inc. stock priceJuly 2025 Patterns & AI Forecasted Entry and Exit Points - ulpravda.ru
What RSI levels show for Agios Pharmaceuticals Inc. (8AP) stockEarnings Recap Summary & Detailed Earnings Play Strategies - Улправда
Market Review: How Agios Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Drop Watch & Technical Buy Zone Confirmation - Улправда
Why Agios Pharmaceuticals Inc. stock is seen as undervalued2025 Trade Ideas & High Return Trade Opportunity Guides - Улправда
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Price Swings & Stepwise Trade Signal Guides - ulpravda.ru
How Agios Pharmaceuticals Inc. stock performs after earnings2025 Market WrapUp & Verified High Yield Trade Plans - Улправда
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? - Yahoo Finance
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock By Investing.com - Investing.com India
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock - Investing.com
Bank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com - Investing.com Nigeria
Here's why shares in Agios Pharmaceuticals popped today - MSN
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) t - GuruFocus
Agios Pharmaceuticals, Inc. Being Investigated on Behalf of Agios Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Agios Pharmaceuticals, Inc. (AGIO): Investor Outlook Highlights A Potential 33% Upside - DirectorsTalk Interviews
JPMorgan Chase & Co. Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $25.00 - MarketBeat
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Agios Pharmaceuticals Inc 주식 (AGIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Milanova Tsveta | Chief Commercial Officer |
Jan 05 '26 |
Sale |
27.02 |
2,872 |
77,601 |
34,793 |
2.09%
0.48%
자본화:
|
볼륨(24시간):